Christopher F Bell

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 34

Top Topics

African American

Disease Activity

Systemic Lupus Erythematosus

Top Venues

Rheumatology and therapy

Lupus science & medicine

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Guillaume Germain, Karen Worley, Sean D MacKnight, Bernard Rubin, Christopher F Bell, François Laliberté, Ana Urosevic, Mei Sheng Duh, Andrew Concoff
Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count. Lupus science & medicine 11 (1) (2024)
Guillaume Germain, Karen Worley, Sean D MacKnight, Bernard Rubin, Christopher F Bell, François Laliberté, Ana Urosevic, Mei Sheng Duh, Andrew Concoff
Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count. Lupus science & medicine 11 (1) (2024)
Christopher F Bell, Daniel C Gibbons, Myriam Drysdale, Helen J Birch, Emily J Lloyd, Vishal Patel, Corinne Carpenter, Katherine Carlson, Ediz S Calay, Arjun Puranik, Tyler E Wagner, John C O'Horo, Raymund R Razonable
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records. PloS one 19 (7) (2024)
Christopher F Bell, Priyanka Jain, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh, null null
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C). Clinical drug investigation 44 (3) (2024)
Christopher F Bell, Priyanka Jain, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh, null null
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C). Clinical drug investigation (2024)
Christopher F Bell, Benjamin Wu, Shirley P Huang, Bernard Rubin, Carlyne M Averell, Benjamin Chastek, Erin M Hulbert
Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period. BMC health services research 24 (1) (2024)
Guillaume Germain, Karen Worley, Sean D MacKnight, Bernard Rubin, Christopher F Bell, François Laliberté, Ana Urosevic, Mei Sheng Duh, Andrew Concoff
Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count. Lupus science & medicine 11 (1) (2024)
Christopher F Bell, Priyanka Jain, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh, null null
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C). Clinical drug investigation 44 (3) (2024)
Christopher F Bell, Daniel C Gibbons, Myriam Drysdale, Helen J Birch, Emily J Lloyd, Vishal Patel, Corinne Carpenter, Katherine Carlson, Ediz S Calay, Arjun Puranik, Tyler E Wagner, John C O'Horo, Raymund R Razonable
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records. PloS one 19 (7) (2024)
Christopher F Bell, Priyanka Jain, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh, null null
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C). Clinical drug investigation 44 (3) (2024)
Christopher F Bell, Priyanka Jain, Raj Desai, Daniel C Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J Birch, Emily J Lloyd, Adina Zhang, Mei Sheng Duh, null null
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C). Clinical drug investigation 44 (3) (2024)
Guillaume Germain, Karen Worley, Sean D MacKnight, Bernard Rubin, Christopher F Bell, François Laliberté, Ana Urosevic, Mei Sheng Duh, Andrew Concoff
Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count. Lupus science & medicine 11 (1) (2024)
Christopher F Bell, Benjamin Wu, Shirley P Huang, Bernard Rubin, Carlyne M Averell, Benjamin Chastek, Erin M Hulbert
Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period. BMC health services research 24 (1) (2024)
Christopher F Bell, Benjamin Wu, Shirley P Huang, Bernard Rubin, Carlyne M Averell, Benjamin Chastek, Erin M Hulbert
Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period. BMC health services research 24 (1) (2024)
Christopher F Bell, Daniel C Gibbons, Myriam Drysdale, Helen J Birch, Emily J Lloyd, Vishal Patel, Corinne Carpenter, Katherine Carlson, Ediz S Calay, Arjun Puranik, Tyler E Wagner, John C O'Horo, Raymund R Razonable
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records. PloS one 19 (7) (2024)
Maral DerSarkissian, Yuqian M Gu, Mei Sheng Duh, John Benson, Shirley P Huang, Carlyne Averell, Jensen Vu, Min-Jung Wang, Christopher F Bell
Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study. ACR open rheumatology (2023)
Christopher F Bell, Jake Chung, Bernard Rubin
Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study. Rheumatology and therapy 10 (2) (2023)
Christopher F Bell, Jake Chung, Bernard Rubin
Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study. Rheumatology and therapy 10 (2) (2023)
Shirley P Huang, Amy Guisinger, Carlyne Averell, Christopher F Bell, Bernie Rubin
Clinical and Economic Burden of Systemic Lupus Erythematosus in the Years Preceding End-Stage Kidney Disease Diagnosis: A Retrospective Observational Study. Rheumatology and therapy (2023)
Christopher F Bell, Jake Chung, Bernard Rubin
Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study. Rheumatology and therapy 10 (2) (2023)
Christopher F Bell, Jake Chung, Bernard Rubin
Correction: Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study. Rheumatology and therapy (2023)
Christopher F Bell, Jake Chung, Bernard Rubin
Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study. Rheumatology and therapy 10 (2) (2023)
Christopher F Bell, Jake Chung, Bernard Rubin
Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study. Rheumatology and therapy (2023)
Christopher F Bell, Shirley P Huang, Anissa Cyhaniuk, Carlyne M Averell
The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Lupus 32 (2) (2022)
Christopher F Bell, Shirley P Huang, Louise H Yu, Maral DerSarkissian, Guillaume Germain, Andrew L Concoff, Carlyne M Averell, Bernard Rubin, Yuqian M Gu, Mei Sheng Duh, Daniel J Wallace
A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA. Rheumatology and therapy (2022)
Christopher F Bell, Mayank R Ajmera, Juliana Meyers
An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States. Lupus 31 (2) (2022)
Christopher F Bell, Shirley P Huang, Anissa Cyhaniuk, Carlyne M Averell
The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Lupus (2022)
Christopher F Bell, Shirley P Huang, Anissa Cyhaniuk, Carlyne M Averell
The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Lupus 32 (2) (2022)
Shirley P Huang, Sonya J Snedecor, Sakina Nanji, Emily Lloyd, Christopher F Bell
Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review. Rheumatology and therapy 9 (4) (2022)
Christopher F Bell, Shirley P Huang, Anissa Cyhaniuk, Carlyne M Averell
The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Lupus 32 (2) (2022)
Nevin Hammam, Michael Evans, Christopher F Bell, Kerry Gairy, Rebecca Grainger, Gabriela Schmajuk
Evaluating the Use of Glucocorticoids Among Belimumab-Treated Patients With Systemic Lupus Erythematosus in Real-World Settings Using the Rheumatology Informatics System for Effectiveness Registry. ACR open rheumatology 4 (10) (2022)
Tasneem Lokhandwala, Binglin Yue, Anna D Coutinho, Christopher F Bell
Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus. Lupus science & medicine 8 (1) (2021)
Christopher F Bell, Julie Priest, Marni Stott-Miller, Hong Kan, Justyna Amelio, Xue Song, Brendan Limone, Virginia Noxon, Karen H Costenbader
Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA. Lupus science & medicine 7 (1) (2020)
Christopher F Bell, Matthew Lau, Melody Lee, Christine Poulos
Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE. Clinical rheumatology 40 (2) (2020)